Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Strengthening Biomarker Research in Canadian Cancer Clinical Trials: A Pathology-Focused White Paper.

Current oncology (Toronto, Ont.)·2026
Same author

The bench.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2026
Same author

Clinical and molecular correlates of circulating tumor fraction in patients with metastatic pancreatic ductal adenocarcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

The UCEIS and UC-100 score were responsive endoscopic and global indices in a phase 2 trial of ulcerative colitis.

Crohn's & colitis 360·2026
Same author

CANLead: Canada as a Phase 1 Clinical Trial Leader - Opportunities, Initiatives, and Collaborative Innovation to Elevate National Competitiveness.

The oncologist·2026
Same author

Recommendations for Pathologist-Led Deployment of Artificial Intelligence Tools as Laboratory-Developed Tests.

Laboratory investigation; a journal of technical methods and pathology·2026
Same journal

Validation of the Taiwan Cancer Frailty Tool for Screening and Prognosis in Non-older Patients With Cancer: A Prospective Multicenter Study.

Cancer control : journal of the Moffitt Cancer Center·2026
Same journal

Improving Breast Cancer Outcomes by Enhanced Activities in Early Detection and Diagnosis: An Umbrella Review and Meta-Analyses of Randomised Controlled Trials in High-Income Contexts With Universal Healthcare Coverage.

Cancer control : journal of the Moffitt Cancer Center·2026
Same journal

Prevalence and Determinants of Female Sexual Dysfunction, and Its Association With Neurotrophic Biomarkers in Gynaecological Cancer Survivors: A Cross-Sectional Study.

Cancer control : journal of the Moffitt Cancer Center·2026
Same journal

Evaluating A Patient-Led Health Literacy Program for People Living With Metastatic Breast Cancer.

Cancer control : journal of the Moffitt Cancer Center·2026
Same journal

Clinical Diagnosis Codes Identify Patients Unlikely to Receive Orders for Fecal Immunochemical Tests.

Cancer control : journal of the Moffitt Cancer Center·2026
Same journal

Passing the Baton: Succession Planning and Mentorship for Cancer Control in Low- and Middle-Income Countries.

Cancer control : journal of the Moffitt Cancer Center·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

7.8K

Comparison of Lanreotide and Octreotide LAR Use and Outcomes for Gastrointestinal Neuroendocrine Tumors in British

Ashley Paul1, Shehara Mendis1, Michael Diaz-Stewart2

  • 1BC Cancer, Vancouver, BC, Canada.

Cancer Control : Journal of the Moffitt Cancer Center
|February 19, 2026
PubMed
Summary
This summary is machine-generated.

Lanreotide (LAN) demonstrated improved progression-free survival and overall survival in neuroendocrine tumor (NET) patients compared to octreotide LAR (OCT). LAN was also associated with less need for rescue medication, suggesting potential benefits in NET management.

Keywords:
NETcancerlanreotideoctreotidesomatostatin

More Related Videos

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

18.2K
Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

895

Related Experiment Videos

Last Updated: May 5, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

7.8K
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

18.2K
Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

895

Area of Science:

  • Endocrinology
  • Oncology
  • Pharmacology

Background:

  • Long-acting somatostatin analogues (LA-SSAs), octreotide LAR (OCT) and lanreotide (LAN), are used to manage neuroendocrine tumors (NETs).
  • While both improve progression-free survival (PFS), no direct head-to-head comparisons exist for efficacy in specific NET populations.

Purpose of the Study:

  • To compare treatment patterns and efficacy of LAN versus OCT in a population-based cohort of small bowel and pancreatic NET patients.
  • To evaluate the impact of these LA-SSAs on progression-free survival (PFS) and overall survival (OS).

Main Methods:

  • Retrospective chart review of 321 patients with small bowel or pancreatic NETs treated with either LAN or OCT.
  • Analysis of patient demographics, tumor characteristics, treatment patterns, and survival outcomes (PFS and OS).
  • Sensitivity analysis was performed considering reimbursement eras.

Main Results:

  • Lanreotide (LAN) was more frequently used in higher-grade tumors (P=0.019).
  • Patients receiving LAN showed significantly longer PFS (HR 0.60, P=0.011) and OS (HR 0.45, P=0.016) compared to those on OCT.
  • Similar dose escalation rates were observed, but LAN use was associated with numerically less short-acting octreotide use for rescue.

Conclusions:

  • In this population-based cohort, lanreotide (LAN) was associated with improved PFS and OS, and reduced need for short-acting octreotide rescue compared to octreotide LAR (OCT).
  • Findings suggest potential benefits of LAN in NET management but require cautious interpretation due to the retrospective design.
  • Prospective or head-to-head studies are warranted to confirm these efficacy findings.